C4 Therapeutics Q2 Net Loss $23.6M, EPS $0.18; Cemsidomide Trials On Track
C4 Therapeutics reported a net loss of $23.6 million, or $0.18 per share, for Q2 2026, an improvement from a net loss of $26.0 million, or $0.37 per share, in Q2 2025. Revenue for the quarter was $6.6 million, slightly up from $6.5 million year-over-year. The company's cash, cash equivalents, and marketable securities stood at $300.4 million as of June 30, 2026, providing a cash runway until the end of 2028. Key clinical programs for cemsidomide, including the Phase 2 MOMENTUM trial and Phase 1b combination trials, remain on track for data readouts in 2027, alongside a new collaboration with Roche and $33.5 million raised through its ATM program.
Key Highlights
- Net loss for Q2 2026 was $23.6 million, down from $26.0 million in Q2 2025.
- Net loss per share for Q2 2026 was $0.18, compared to $0.37 in Q2 2025.
- Total revenue for Q2 2026 was $6.6 million, up from $6.5 million in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $300.4 million as of June 30, 2026.
- Company expects current cash to fund operations until the end of 2028.
- Received a $20 million upfront payment from the new Roche DAC collaboration in May 2026.
- Raised approximately $33.5 million in net proceeds through its ATM program in Q2 2026.
- Cemsidomide Phase 2 MOMENTUM trial is on track for initial ORR data in 2H 2027.
Price Impact
More from CCCC
C4 Therapeutics Secures Roche DAC Partnership with $20M Upfront, $1B+ Milestones
C4 Therapeutics Stockholders Elect Directors, Approve Plan Amendment
C4 Therapeutics Presents Promising Phase 1 Data for Cemsidomide in Multiple Myeloma